萊美藥業(300006.SZ):實控人將變更為廣西國資委
格隆匯11月25日丨萊美藥業(300006.SZ)公佈,公司控股股東邱宇與南岸城建終止《戰略合作意向協議》,與中恆集團(600252.SH)新簽訂《戰略合作框架協議》,將其所持公司22.71%股份對應的表決權等委託給中恆集團行使。
屆時,中恆集團或將成為公司單一擁有表決權份額最大的股東,公司實控人將變更為廣西壯族自治區國資委。同時,中恆集團承諾將在該協議簽署並生效後的12個月內從二級市場直接購買或受讓大股東所持有的公司股票,增持比例不低於公司總股本的5%。
此次交易完成後,公司通過引入國資戰略投資方有利於公司經營穩定和持續增長,後續雙方通過產業協同合作、金融資源支持等方式,促進公司在生物醫藥產業進一步做大做強。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.